

LETTERS TO THE EDITOR

# Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019


To the Editor,

We read with interest the article by Abraham and Krasnodembskaya regarding mesenchymal stem cells (MSCs)-derived extracellular vesicles for the treatment of acute respiratory distress syndrome (ARDS).<sup>1</sup> Since December 2019, the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, has drawn worldwide attention. As of February 26, 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had infected more than 82 000 people and had led to 2800 deaths from acute lung injury (ALI) and ARDS worldwide. Unfortunately, the numbers of both infected patients and fatalities are still growing and no effective drugs are clinically approved.

Similar to two other lethal coronaviruses, SARS-CoV and MERS-CoV, SARS-CoV-2 induces excessive and aberrant host immune responses that are always accompanied by cytokine storms (CS) and subsequent ALI or even ARDS, resulting in multiple organ

failure and death.<sup>2</sup> Even in patients who were treated in intensive care units for CS, persistent inflammation led to serious sequelae of lung fibrosis, causing lung dysfunction and reduced quality of life.<sup>3</sup> Although corticosteroid given to reverse catabolism in critical illness decreased the mortality after SARS and MERS infection, the clinical application of corticosteroid has been restricted in COVID-19, considering its delay in virus clearance and complications in survivors. There is an urgent need for advancing therapeutic interventions with both functions for CS suppression and lung reparation in critical patients.

MSCs have been found to be capable of modulating immune responses, thereby reducing inflammation as well as immunopathology and protecting alveolar epithelial cells during ALI and ARDS.<sup>4-7</sup> More importantly, MSCs were efficacious in reducing the nonproductive inflammation and in promoting lung generation in a phase 2 clinical trial (NCT03608592), as well as in patients with ALI and ARDS in clinical



**FIGURE 1** Potential mechanism of MSCs in the treatment of severe COVID-19

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2020 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

practice.<sup>8-10</sup> As a result, MSCs may alleviate the SARS-CoV-2-derived CS and ARDS, and have a potential effect on the treatment of subsequent chronic respiratory dysfunction and lung fibrosis.

To alleviate acute respiratory disease and reverse pulmonary fibrosis in intensive-care SARS-CoV-2-infected patients, three curative properties of MSCs have emerged (Figure 1): (a) directly inducing the apoptosis of activated T cells to relieve the aberrant and excessive immune responses, (b) homing toward specific injuries of lung to maintain homeostasis as well as promote regeneration, and (c) releasing cytokines to diminish inflammation and extracellular vesicles (EVs) to stimulate tissue repair.<sup>1</sup> Notably, it has been proved that MSC-released cytokines can potently inhibit neutrophil intravasation and enhance the differentiation of macrophages.<sup>5,6</sup> Moreover, these MSC-released EVs can deliver microRNA, mRNA, DNA, proteins, and metabolites into host cells in specific injuries of the lung to promote lung repair as well as regeneration and restore lung function.<sup>1</sup>

As the continuing epidemic threat of SARS-CoV-2 to global health and the fast-growing number of fatalities, advancing new therapeutic development becomes central or primary to minimize the death and sequelae from SARS-CoV-2 infection. Thus, MSCs should be considered as a potential treatment for these critical patients. A recent clinical trial (NCT04252118) is expected to verify its efficacy and safety.

#### CONFLICT OF INTEREST


The authors declared no potential conflicts of interest.

Fanpu Ji<sup>1</sup>

Liya Li<sup>2</sup>

Zongfang Li<sup>3,4</sup>

Yan Jin<sup>2</sup> 

Wenjia Liu<sup>2</sup> 

<sup>1</sup>Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China

<sup>2</sup>State Key Laboratory of Military Stomatology, Center for Tissue Engineering, School of Stomatology, Fourth Military Medical University, Xi'an, People's Republic of China

<sup>3</sup>National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, the Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, People's Republic of China

<sup>4</sup>Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry of Education of China, Xi'an, People's Republic of China

#### ORCID

Yan Jin  <https://orcid.org/0000-0002-2586-1152>

Wenjia Liu  <https://orcid.org/0000-0003-1018-3587>

#### REFERENCES

1. Abraham A, Krasnodembskaya A. Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. *Stem Cells Transl Med.* 2020;9:28-38.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. *Lancet.* 2020;395:497-506.
3. Xie L, Liu Y, Fan B, et al. Dynamic changes of serum SARS-coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge. *Respir Res.* 2005;6:5.
4. Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? *Trends Immunol.* 2007;28:219-226.
5. Xu AL, Rodriguez LA, Walker KP, et al. Mesenchymal stem cells reconditioned in their own serum exhibit augmented therapeutic properties in the setting of acute respiratory distress syndrome. *Stem Cells Transl Med.* 2019;8:1092-1106.
6. Morrison TJ, Jackson MV, Cunningham EK, et al. Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. *Am J Respir Crit Care Med.* 2017;196:1275-1286.
7. Johnson CL, Soeder Y, Dahlke MH. Concise review: mesenchymal stromal cell-based approaches for the treatment of acute respiratory distress and sepsis syndromes. *Stem Cells Transl Med.* 2017;6(4):1141-1151.
8. Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. *Lancet Respir Med.* 2019;7:154-162.
9. Loy H, Kuok DIT, Hui KPY, et al. Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza A (H5N1) virus-associated acute lung injury. *J Infect Dis.* 2019;219:186-196.
10. Simonson OE, Mougiakakos D, Heldring N, et al. In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. *Stem Cells Transl Med.* 2015;4:1199-1213.